Phase 3CompletedHealthspan endpoint
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)
A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial
- Sponsor
- Amgen (Industry)
- Enrollment
- 1,974 enrolled
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab; Placebo; Background Statin Therapy
- Ages
- adults, older adults
- Registry
- NCT02207634, EUCTR2014-001976-75
Full record on ClinicalTrials.gov
From the registry
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
Primary outcomes
- Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score
History
Results first posted
Last registry update
Primary completion
Started
Registered